Cargando…

Multi-Parametric Deep Learning Model for Prediction of Overall Survival after Postoperative Concurrent Chemoradiotherapy in Glioblastoma Patients

This study aimed to investigate the performance of a deep learning-based survival-prediction model, which predicts the overall survival (OS) time of glioblastoma patients who have received surgery followed by concurrent chemoradiotherapy (CCRT). The medical records of glioblastoma patients who had r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Han Gyul, Cheon, Wonjoong, Jeong, Sang Woon, Kim, Hye Seung, Kim, Kyunga, Nam, Heerim, Han, Youngyih, Lim, Do Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465791/ https://www.ncbi.nlm.nih.gov/pubmed/32823939 http://dx.doi.org/10.3390/cancers12082284

Ejemplares similares

Clinical Outcomes of Moderately Hypofractionated Concurrent Chemoradiotherapy for Newly Diagnosed Glioblastoma
por: Kim, Nalee, et al.
Publicado: (2023)

Clinical applicability of deep learning-based respiratory signal prediction models for four-dimensional radiation therapy
por: Jeong, Sangwoon, et al.
Publicado: (2022)

Development of a time-resolved mirrorless scintillation detector
por: Cheon, Wonjoong, et al.
Publicado: (2021)

Development of a real-time internal and external marker tracking system for particle therapy: a phantom study using patient tumor trajectory data
por: Cho, Junsang, et al.
Publicado: (2017)

Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging
por: Lee, Eun Kyoung, et al.
Publicado: (2015)

Machine learning model for predicting excessive muscle loss during neoadjuvant chemoradiotherapy in oesophageal cancer
por: Yoon, Han Gyul, et al.
Publicado: (2021)

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea
por: Kim, Byung Sup, et al.
Publicado: (2017)

Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion
por: Han, Sojung, et al.
Publicado: (2020)

Comparison between preoperative and postoperative concurrent chemoradiotherapy for rectal cancer: an institutional analysis
por: Lee, Jeong Won, et al.
Publicado: (2013)

Harnessing Nuclear Energy to Gold Nanoparticles for the Concurrent Chemoradiotherapy of Glioblastoma
por: Li, Jui-Ping, et al.
Publicado: (2023)

Levetiracetam as a sensitizer of concurrent chemoradiotherapy in newly diagnosed glioblastoma: An open‐label phase 2 study
por: Hwang, Kihwan, et al.
Publicado: (2021)

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Advanced Oral Cavity Cancer in the Era of Modern Radiation Techniques
por: Kim, Tae Hyung, et al.
Publicado: (2021)

Obesity is associated with improved postoperative overall survival, independent of skeletal muscle mass in lung adenocarcinoma
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Chemoradiotherapy Alters Protein Expression in Glioblastoma Multiforme
por: Hwang, Mina, et al.
Publicado: (2020)

Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy
por: Choi, Yunseon, et al.
Publicado: (2014)

Feasibility of an Interactive Health Coaching Mobile App to Prevent Malnutrition and Muscle Loss in Esophageal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy: Prospective Pilot Study
por: Yang, Kyungmi, et al.
Publicado: (2021)

Concurrent chemoradiotherapy improves survival outcome in muscle-invasive bladder cancer
por: Byun, Sang Jun, et al.
Publicado: (2015)

Definitive concurrent chemoradiotherapy in locally advanced pancreatic cancer
por: Kwak, Yoo-Kang, et al.
Publicado: (2014)

Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages
por: Li, Guanzhang, et al.
Publicado: (2019)

Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients
por: Zhang, Maochen, et al.
Publicado: (2020)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients with cervical nodal necrosis
por: Lan, Mei, et al.
Publicado: (2017)

Postoperative chemoradiotherapy in high risk locally advanced gastric cancer
por: Song, Sanghyuk, et al.
Publicado: (2012)

The single institutional outcome of postoperative radiotherapy and concurrent chemoradiotherapy in resected non-small cell lung cancer
por: Lee, Hyo Chun, et al.
Publicado: (2014)

Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients
por: Kang, Jingjing, et al.
Publicado: (2018)

Improved overall survival is associated with adjuvant chemotherapy after definitive concurrent chemoradiotherapy for N3 nasopharyngeal cancer
por: Tsai, Mu-Hung, et al.
Publicado: (2022)

Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma
por: Xu, Guoqiang, et al.
Publicado: (2021)

Neoadjuvant therapy of metformin is associated with good tumor response after preoperative concurrent chemoradiotherapy for rectal cancer
por: Han, Jeonghee, et al.
Publicado: (2022)

Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: A systematic review and meta-analysis
por: Liu, Haonan, et al.
Publicado: (2022)

Study on the Application Value of Concurrent Chemoradiotherapy and Clinical Nursing Pathway for Postoperative Patients with Esophageal Cancer
por: Yang, Jinglei, et al.
Publicado: (2022)

Bronchopleural Fistula After Concurrent Chemoradiotherapy
por: van de Pas, Jorien M., et al.
Publicado: (2020)

High Mean Corpuscular Volume as a Predictor of Poor Overall Survival in Patients with Esophageal Cancer Receiving Concurrent Chemoradiotherapy
por: Li, Ke-jie, et al.
Publicado: (2020)

Clinical Factors to Predict the Response to Concurrent Chemoradiotherapy and Survival in Esophageal Cancer Patients
por: Nam, Su Youn, et al.
Publicado: (2020)

Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma
por: Zhou, Xi-Lei, et al.
Publicado: (2021)

Association between treatment-related lymphopenia and survival in glioblastoma patients following postoperative chemoradiotherapy
por: Mapelli, Roberto, et al.
Publicado: (2021)

Liver-Directed Concurrent Chemoradiotherapy versus Sorafenib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Kim, Jina, et al.
Publicado: (2022)

Association between survival and levetiracetam use in glioblastoma patients treated with temozolomide chemoradiotherapy
por: Roh, Tae Hoon, et al.
Publicado: (2020)

Analysis of the Prognostic Factors for Distant Metastasis after Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Head and Neck Cancer
por: Kim, Dong Hyun, et al.
Publicado: (2015)

Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study
por: Choi, Younak, et al.
Publicado: (2016)

Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma
por: Setakornnukul, Jiraporn, et al.
Publicado: (2018)

Concurrent chemoradiotherapy for elderly patients with stage III non-small cell lung cancer
por: Kang, Ki Mun, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_dgv0mshj786uhh7mfjkanpsmph